Risk of Cardiovascular Disease in Women With a History of Hyperemesis Gravidarum, With and Without Preeclampsia.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
06 06 2023
Historique:
medline: 7 6 2023
pubmed: 1 6 2023
entrez: 1 6 2023
Statut: ppublish

Résumé

Background Hyperemesis gravidarum is associated with preeclampsia, but it is unclear whether hyperemesis gravidarum is a risk factor for cardiovascular disease. We assessed the long-term risk of cardiovascular disease in women who experienced hyperemesis gravidarum with or without preeclampsia. Methods and Results We analyzed a longitudinal cohort of 1 413 166 pregnant women in Quebec between 1989 and 2021. Women were followed from their first pregnancy up to 3 decades later. We computed hazard ratios (HRs) and 95% CIs for the association of hyperemesis gravidarum, preeclampsia, or both conditions with subsequent risk of cardiovascular hospitalization using Cox regression models adjusted for baseline characteristics. Among 1 413 166 women, 16 288 (1.2%) had hyperemesis gravidarum only, 69 645 (4.9%) preeclampsia only, and 1103 (0.08%) had both conditions. After 32 years of follow-up, cardiovascular disease incidence was 17.7 per 100 women with hyperemesis gravidarum only, 28.2 per 100 women with preeclampsia only, 30.9 per 100 women with both exposures, and 14.0 per 100 women with neither exposure. Compared with no exposure, women with both hyperemesis and preeclampsia had the greatest risk of cardiovascular hospitalization (HR, 3.54 [95% CI, 3.03-4.14]), followed by women with preeclampsia only (HR, 2.58 [95% CI, 2.51-2.64]) and hyperemesis only (HR, 1.46 [95% CI, 1.38-1.54]). Having both hyperemesis gravidarum and preeclampsia was strongly associated with valve disease (HR, 3.38 [95% CI, 1.69-6.75]), heart failure (HR, 3.43 [95% CI, 1.79-6.59]), and cardiomyopathy (HR, 4.17 [95% CI, 1.99-8.76]). Conclusions Hyperemesis gravidarum is associated with the development of cardiovascular disease, whether preeclampsia is present or not.

Identifiants

pubmed: 37259983
doi: 10.1161/JAHA.122.029298
pmc: PMC10382009
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e029298

Commentaires et corrections

Type : CommentIn

Références

Circ Res. 2022 Feb 18;130(4):652-672
pubmed: 35175837
Cardiovasc Res. 2014 Mar 15;101(4):561-70
pubmed: 24448313
Circulation. 2018 May 29;137(22):2321-2331
pubmed: 29610262
Lancet. 2020 Mar 7;395(10226):795-808
pubmed: 31492503
Paediatr Perinat Epidemiol. 2018 Jan;32(1):40-51
pubmed: 28984372
Cell Mol Life Sci. 2014 Feb;71(4):549-74
pubmed: 23649149
Cancer Epidemiol Biomarkers Prev. 2022 Oct 4;31(10):1919-1925
pubmed: 35839462
Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2):
pubmed: 28228456
PLoS One. 2013 Dec 11;8(12):e81612
pubmed: 24349097
Circ Res. 2006 Feb 17;98(3):351-60
pubmed: 16397141
Pregnancy Hypertens. 2021 Mar;23:140-154
pubmed: 33388730
J Am Heart Assoc. 2016 Sep 28;5(10):
pubmed: 27680665
Cells. 2021 Nov 18;10(11):
pubmed: 34831442
J Matern Fetal Neonatal Med. 2020 Feb;33(3):385-389
pubmed: 29945479
Medicine (Baltimore). 2022 Jul 29;101(30):e29646
pubmed: 35905265
Pregnancy Hypertens. 2018 Apr;12:129-135
pubmed: 29858105
Clin Chem. 2017 Jan;63(1):140-151
pubmed: 28062617
Stat Med. 2007 Mar 15;26(6):1343-59
pubmed: 16955538
Nat Med. 2011 May;17(5):581-8
pubmed: 21516086
Heart. 2017 Feb;103(3):235-243
pubmed: 27530133
Trends Cardiovasc Med. 2011 Oct;21(7):188-93
pubmed: 22867697
Int J Mol Sci. 2019 Aug 30;20(17):
pubmed: 31480243
BJOG. 2013 Apr;120(5):541-7
pubmed: 23360164
Geburtshilfe Frauenheilkd. 2019 Apr;79(4):382-388
pubmed: 31000883
Pharmacology. 2017;100(3-4):161-171
pubmed: 28641304
BMC Pregnancy Childbirth. 2019 Dec 19;19(1):508
pubmed: 31856759
Chronic Dis Can. 2009;29(4):178-91
pubmed: 19804682
Hypertension. 2020 Mar;75(3):788-795
pubmed: 32008431
Exp Ther Med. 2021 Jun;21(6):642
pubmed: 33968173
J Am Coll Cardiol. 2020 Oct 6;76(14):1690-1702
pubmed: 33004135
Ann Epidemiol. 2021 Jul;59:10-15
pubmed: 33798708
Lancet. 2021 Jul 24;398(10297):341-354
pubmed: 34051884
PLoS One. 2019 Jun 12;14(6):e0218051
pubmed: 31188868
J Am Heart Assoc. 2021 Aug 17;10(16):e020302
pubmed: 34387117
JAMA. 2015 Oct 20;314(15):1588-98
pubmed: 26501535
Lancet. 2005 Nov 19;366(9499):1797-803
pubmed: 16298217

Auteurs

Bianca Cécile (B)

Faculty of Medicine University of Montreal Montreal QC Canada.

Brian J Potter (BJ)

University of Montreal Hospital Research Centre Montreal QC Canada.
Division of Cardiology, Department of Medicine University of Montreal Hospital Centre QC Montreal Canada.

Antoine Lewin (A)

Medical Affairs and Innovation, Hema-Quebec Montreal QC Canada.

Jessica Healy-Profitós (J)

University of Montreal Hospital Research Centre Montreal QC Canada.
Institut national de santé publique du Québec Montreal QC Canada.

Émilie Brousseau (É)

University of Montreal Hospital Research Centre Montreal QC Canada.
Institut national de santé publique du Québec Montreal QC Canada.

Nathalie Auger (N)

University of Montreal Hospital Research Centre Montreal QC Canada.
Institut national de santé publique du Québec Montreal QC Canada.
Department of Epidemiology, Biostatistics, and Occupational Health McGill University Montreal QC Canada.
Department of Social and Preventive Medicine, School of Public Health University of Montreal Montreal QC Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH